Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FiREBOLT study of LY4337713 in FAP-positive solid tumors
NL-OMON61360Phase 1Not yet recruiting
- Sponsor
- Eli Lilly and Company
- Start
- Aug 2026
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 1, single-arm trial of retatrutide in ovarian cancer, breast cancer, Pancreatic neoplasia and 5 more, sponsored by Eli Lilly and Company. Primary endpoint: Primary endpoint(s). Planned start Aug 2026; status: not yet recruiting.
02
Drugs
03
Conditions
ovarian cancerbreast cancerPancreatic neoplasiacolorectal cancer (CRC)esophageal cancer
Beyond the preview
Go deeper on NL-OMON61360.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON61360.